BH3:FRA
PTC Therapeutics, Inc.
€ ५५.००
arrow_downward
-०.६१%(-०.३४) 1D
अक्टोबर ९, २२:००:०० GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€ ५५.००
High
€ ५५.००
Low
€ ५५.००
Mkt. cap
५.४० अरब
Avg. vol.
०.००
Volume
०.००
52-wk high
€ ७७.०२
52-wk low
€ ५२.५०
No. of employees
९९१
Open
€ ५५.००
High
€ ५५.००
Low
€ ५५.००
Mkt. cap
५.४० अरब
Avg. vol.
०.००
Volume
०.००
52-wk high
€ ७७.०२
52-wk low
€ ५२.५०
No. of employees
९९१
News stories
From web sources and news partners
Investing.com Nigeria
·
५ घण्टा पहिले
Form 144 PTC THERAPEUTICS For: 10 October By Investing.com
MarketBeat
·
२३ घण्टा पहिले
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages
Investing.com UK
·
१ दिन पहिले
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Stock Titan
·
१ दिन पहिले
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees९९१
Founded१९९८ जनवरी १
HeadquartersWarren, न्यु जर्सी, संयुक्त राज्य अमेरिका
Sector-
Websiteptcbio.com